Hepatocellular carcinoma risk in HBeAg‐negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|2|120-127

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.2, 2015-02, pp. : 120-127

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical outcomes after interruption of entecavir therapy in HBeAg‐negative chronic hepatitis B patients with compensated cirrhosis

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 10, 2015-11 ,pp. : 1182-1191

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical outcomes after interruption of entecavir therapy in HBeAg‐negative chronic hepatitis B patients with compensated cirrhosis

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 10, 2015-11 ,pp. : 1182-1191

John Wiley & Sons Inc

Access to resources Recommend Favorite

On‐treatment prediction of sustained response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B patients

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 5, 2015-05 ,pp. : 1540-1548

John Wiley & Sons Inc

Access to resources Recommend Favorite

Serum HBsAg kinetics and usefulness of interferon‐inducible protein 10 serum in HBeAg‐negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 12, 2015-12 ,pp. : 1079-1087

John Wiley & Sons Inc

Access to resources Recommend Favorite

IFNL4 rs368234815 and rs117648444 variants predict off‐treatment HBsAg seroclearance in IFN‐treated HBeAg‐negative chronic hepatitis B patients

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. 3, 2018-03 ,pp. : 417-423

John Wiley & Sons Inc

Access to resources Recommend Favorite